Adding methotrexate to adalimumab (Humira, AbbVie) in axial spondyloarthritis was associated with reduced immunogenicity, and prolonged co-medication was associated with long-term maintenance of adalimumab, say researchers recently writing in RMD Open: Rheumatic & Musculoskeletal Diseases.
Bone mineral density was preserved over a three-year period in patients with rheumatoid arthritis treated with biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDS) but declined in those who received only conventional-synthetic DMARDs, say researchers recently writing in Rheumatology.
Most women with rheumatic and musculoskeletal diseases will have successful pregnancies with the aid of medical planning, treatment and monitoring. These can be high risk pregnancies for both mother and child. The American College of Rheumatology recently issued treatment guidelines for the management of reproductive health in patients with rheumatic or musculoskeletal disease. Here are takeaways from the guidelines.
The FDA has expanded the indication of the over-the-counter pain reliever ActiPatch (BioElectronics Corp.) to include all musculoskeletal pain. Learn more about this and other recent drug approvals in this news brief.
The U.S. Food and Drug Administration has approved the use of an intravenous form of the pain reliever meloxicam (Anjeso, Baudax Bio) for the relief of moderate to severe pain.
A study of 312,081 pregnant women with rheumatoid arthritis, spondyloarthritis or no inflammatory arthritis, finds that women with rheumatoid arthritis are more likely to have pregnancy complications.
New this week: The American College of Rheumatology has issued treatment guidelines for the management of reproductive health in rheumatic and musculoskeletal diseases. They include 12 ungraded good practice statements and 131 graded recommendations for all female patients considering becoming pregnant.
In this week's news roundup, we focus on skin cancer rates associated with methotrexate use, skin cancer in psoriasis cases and fatigue associated with arthritis.
A double-blind, placebo-controlled, randomized clinical trial has confirmed that low-dose methotrexate is associated with an increased risk of skin cancer, according to a study published this week in the Annals of Internal Medicine.
A systematic review and meta-analysis published today in JAMA Dermatology confirms that psoriasis patients have a slightly increased risk of cancer, specifically, keratinocyte cancer and lymphomas.
Visceral fat appears to be associated with an increased risk of musculoskeletal and widespread pain, according to researchers writing this week in Arthritis and Rheumatology. Plus, a small study shows promise in a new treatment for a rare form of pediatric lupus. This and more news in today's rheumatology news roundup.
The therapeutic management of rheumatoid arthritis has changed over the past 30 years, yet, comorbidities persist. In this quiz, we focus on findings from a new study that examines trends in clinical and patient-reported outcomes for early RA.
New treatments for rheumatoid arthritis can effectively control inflammation, but they do little to improve quality of life indicators—like fatigue—that are important to patients, shows a new study.
Long-term use of tumor necrosis factor inhibitors (TNFi) may show radiographic progression benefit in axial spondyloarthritis, say researchers recently writing in Arthritis & Rheumatology.
In this slideshow we highlight some key facts about the use of supplements to prevent fracture in women and men over the age of 50. Existing treatment guildelines recommend a combination approach with vitamin D and calcium, but some clinical trials are not entirely in agreement. Learn more in this slideshow.